'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Mastellos, Dimitrios C;Blom, Anna M;Connolly, E Sander;Daha, Mohamed R;Geisbrecht, Brian V;Ghebrehiwet, Berhane;Gros, Piet;Hajishengallis, George;Holers, V Michael;Huber-Lang, Markus;Kinoshita, Taroh;Mollnes, Tom E;Montgomery, Robert A;Morgan, B Paul;Nilsson, Bo;Pio, Ruben;Ricklin, Daniel;Risitano, Antonio M;Taylor, Ronald P;Mantovani, Alberto;Ioannidis, John P A;Lambris, John D;
Nature Immunology 2019
323
mastellos2019stealthnature

Keywords

Docking Cancer Cytotoxicity doxorubicin admet cdk7

Access

DOI:
10.1038/s41590-019-0503-1

Citation

ID: 55200
Ref Key: mastellos2019stealthnature
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
55200
Unique Identifier:
10.1038/s41590-019-0503-1
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
4/5
Blockchain Upload Locked

Complete all 5 checklist items to tokenize your article

Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store